Panzol

# Panzol ## Overview - **Classification**: Proton Pump Inhibitor (PPI) - **Mechanism**: Irreversibly blocks the H+/K+-ATPase proton pump in gastric parietal cells, reducing gastric acid secretion. ## Primary Indications 1. **Erosive Esophagitis (GERD)** - Healing and maintenance for acid-related damage. 2. **Zollinger-Ellison Syndrome (ZES)** - Management of pathological hypersecretory conditions. 3. **Helicobacter pylori Eradication** - As part of a multi-drug regimen. 4. **Stress Ulcer Prophylaxis (IV)** - In critically ill patients. ## Adult Dosing ### Standard Dosing **Erosive Esophagitis (GERD)** - **Dose**: **40 mg** - **Frequency**: Once daily - **Route**: Oral (tablet or delayed-release granules) or IV - **Duration**: Up to 8 weeks; maintenance **20-40 mg** daily **Zollinger-Ellison Syndrome/Pathological Hypersecretion** - **Dose**: Initial **40 mg** twice daily - **Frequency**: Twice daily (can increase up to **240 mg/day** divided) - **Route**: Oral or IV **H. pylori Eradication** (as part of triple therapy) - **Dose**: **40 mg** - **Frequency**: Twice daily - **Route**: Oral - **Duration**: 7-14 days **Stress Ulcer Prophylaxis (IV only)** - **Dose**: **40 mg** - **Frequency**: Once daily - **Route**: IV infusion ### Dose Adjustments - **Renal Impairment**: No dose adjustment needed. - **Hepatic Impairment**: For severe impairment (Child-Pugh C), max **20 mg** oral daily. IV use not recommended. - **Elderly Patients**: No specific dose adjustment needed based on age alone. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: Not recommended - **Frequency**: N/A - **Maximum**: N/A - **Special Notes**: Safety and efficacy not established. ### Infants (1-12 months) - **Dose**: Not recommended - **Frequency**: N/A - **Maximum**: N/A - **Special Notes**: Safety and efficacy not established. Limited off-label use in specific cases. ### Children (1-12 years) **Erosive Esophagitis (GERD)** (Oral delayed-release granules) - **Dose**: - **15 to <23 kg**: **20 mg** - **23 to <40 kg**: **20 mg** - **≥40 kg**: **40 mg** - **Frequency**: Once daily - **Maximum**: **40 mg/day** - **Special Notes**: Oral granules mixed with applesauce or apple juice. Do not chew or crush. ### Adolescents (13-18 years) **Erosive Esophagitis (GERD)** - **Dose**: **40 mg** - **Frequency**: Once daily - **Route**: Oral or IV - **Maximum**: **40 mg/day** - **Approach to adult dosing**: Adult GERD doses generally apply. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to pantoprazole or other substituted benzimidazoles. - **Absolute**: Concomitant use with rilpivirine-containing products. ### Common Adverse Effects - **Very Common (>10%)**: Headache, Diarrhea, Nausea, Abdominal pain. - **Common (1-10%)**: Dizziness, Vomiting, Flatulence, Rash. - **Serious but Rare**: Clostridium difficile-associated diarrhea (CDAD), Acute interstitial nephritis, Bone fracture (long-term use), Hypomagnesemia (long-term use), Cyanocobalamin (Vitamin B12) deficiency (long-term use), Fundic gland polyps (long-term use). ### Key Drug Interactions - **Antiretrovirals (e.g., Atazanavir, Rilpivirine)**: Significantly reduced absorption. Avoid concomitant use. - **Warfarin**: Potential for increased INR and bleeding risk. Monitor closely. - **Methotrexate**: Increased and prolonged methotrexate levels. Consider temporary PPI withdrawal or close monitoring. - **Clopidogrel**: Reduced antiplatelet effect. Clinical significance debated; consider alternative PPI or H2 blocker. - **Drugs requiring acidic gastric pH (e.g., Ketoconazole, Iron salts)**: Reduced absorption due to increased gastric pH. ## Monitoring & Follow-up - **Before Treatment**: Consider baseline magnesium and vitamin B12 for anticipated long-term therapy. - **During Treatment**: Monitor for symptom improvement. For long-term use (>3 months), monitor magnesium levels periodically. - **Clinical Signs**: Watch for severe diarrhea (CDAD), new or worsening rash, bone pain, muscle weakness (hypomagnesemia). ## Clinical Pearls - 💡 **Tip 1**: Administer oral doses at least 30 minutes before a meal for optimal absorption. - 💡 **Tip 2**: For IV administration, infusion should be over 15 minutes, typically once daily. - 💡 **Tip 3**: Long-term use (>1 year) increases risks of osteoporotic fractures, hypomagnesemia, and C. difficile infection. Use lowest effective dose for shortest duration. - 💡 **Tip 4**: Rebound acid hypersecretion can occur with abrupt discontinuation of long-term therapy; consider tapering. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.